You are concerned that modified nucleosides in Covid mRNA vaccine are carcinogenic.
According to Pfizer description, vaccine contains 0.3 micrograms of mRNA. The mRNA consists of no less than 3819 nucleotides (nucleosides plus phosphoric group) coding S-protein (1273 amino acids). Which means one nucleotide weighs ~0.08 nanogram. Let’s assume for simplicity that mRNA contains ten modified nucleosides that are the cause of your concern. Together they weigh ~0.8 nanograms. Is it a lot? Imagine a droplet of water - it’s weight is ~300 ng. So, the total weight of ten nucleosides can’t exceed ~1/400th of a water droplet. Most likely, such calculations are over-optimistic and in reality this number is significantly lower. Even if those nucleosides were carcinogenic (and we have no indication they are), their amounts are so miniscule, that we probably inhale hundred times more of carcinogens when we drive a car in a city, every second. It is amazing that such tiny quantities of mRNA can be expressed in a few cells and produce S-protein detected by human immune system which, in turn, elicit immune response - production of antibodies to fight the actual virus.
Do you really judge the human safety of a molecule by its weight or volume?
Please, let the people that do this for a living know. They waste tons of time testing and measuring results. Where have you been?
Ps: these things can be nasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861763/#Sec1title
A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B
Vandana Khungar and Steven-Huy Han
Additional article information
Abstract
Although nucleosides and nucleotides have a good safety record for the treatment of hepatitis B, there have been no systematic reviews on this topic. We searched Medline to include studies of the oral antiviral agents for hepatitis B and adverse events, with at least 48 weeks of follow-up from the initiation of treatment with the drug. Important toxicities include nephrotoxicity, myopathy, and resistance. It is often difficult to ascertain whether an adverse effect is from the study drug or the natural progression of the disease. Further safety data are needed for the newer agents and for all agents with regard to patients with decompensated liver disease, renal dysfunction, the elderly, children, and pregnant women.